Liraglutide Anti-Diabetics maka njikwa shuga ọbara CAS NO.204656-20-2
Nkọwa ngwaahịa
| CAS | 204656-20-2 | Usoro ihe omimi | C172H265N43O51 |
| Arọ Molecular | 3751.20 | Ọdịdị | Ọcha |
| Ọnọdụ Nchekwa | Nguzogide ọkụ, ogo 2-8 | ngwugwu | Aluminom foil akpa / vial |
| Ịdị ọcha | ≥98% | Ụgbọ njem | Chain oyi na nnyefe nchekwa dị jụụ |
Ngwakọta nke Liraglutide
Ihe na-arụ ọrụ:
Liraglutide (analog nke mmadụ glucagon-dị ka peptide-1 (GLP-1) nke yist mepụtara site na teknụzụ recombination nke mkpụrụ ndụ ihe nketa.
Aha kemịkalụ:
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl))))-GLP-1[7-37]
Ngwa ndị ọzọ:
Disodium Hydrogen Phosphate Dihydrate, Propylene Glycol, Hydrochloric Acid na/ma ọ bụ Sodium Hydroxide (dị ka pH Adjusters Only), Phenol, na Mmiri maka ịgba ọgwụ.
Ngwa
Ụdị ọrịa shuga 2
Liraglutide na-akwalite njikwa glucose ọbara.Ọ na-ebelata hyperglycemia metụtara nri (maka awa 24 mgbe nchịkwachara) site na ịba ụba insulin (naanị) mgbe achọrọ ya site na ịbawanye ọkwa glucose, na-egbu oge ịgbasa gastric, yana igbochi secretion prandial glucagon.
Ọ dị mma maka ndị ọrịa ka na-achịkwa shuga ọbara ha na-adịghị mma mgbe oke anabatara metformin ma ọ bụ sulfonylureas naanị.A na-ejikọta ya na metformin ma ọ bụ sulfonylureas.
Ọ na-eme n'ụzọ dabere na glucose, nke pụtara na ọ ga-akpali mmepụta insulin naanị mgbe ọkwa glucose ọbara dị elu karịa nke nkịtị, na-egbochi "overshoot".N'ihi ya, ọ na-egosi ihe ize ndụ nke hypoglycemia.
O nwere ikike igbochi apoptosis na mkpali mmụgharị nke mkpụrụ ndụ beta (nke a na-ahụ na ọmụmụ anụmanụ).
Ọ na-ebelata agụụ ma na-egbochi ibu ahụ, dịka egosiri na ọmụmụ isi na isi megide glimepiride.
Omume ọgwụ
Liraglutide bụ analog GLP-1 nwere usoro 97% homology na GLP-1 mmadụ, nke nwere ike ijikọ ma rụọ ọrụ GLP-1 nnabata.Onye na-anabata GLP-1 bụ ebumnuche nke nwa amaala GLP-1, homonụ incretin endogenous nke na-akwalite mmepụta insulin na-adabere na glucose sitere na sel beta pancreatic.N'adịghị ka GLP-1 nwa amaala, profaịlụ ọgwụ na ọgwụ ọgwụ nke liraglutide n'ime mmadụ dabara adaba maka usoro ọgwụgwọ otu ugboro kwa ụbọchị.Mgbe ogwugwu subcutaneous gasịrị, usoro ya nke ime ihe na-adịte aka na-agụnye: njikọ onwe onye nke na-ebelata absorption;na-ejikọta ya na albumin;Nkwụsi ike nke enzyme dị elu ma si otú a dị ogologo ndụ ọkara ndụ plasma.
A na-arụ ọrụ nke liraglutide site na mmekọrịta ya na onye na-anabata GLP-1, na-ebute mmụba nke adenosine monophosphate cyclic (cAMP).Liraglutide na-akpali mmepụta insulin n'ụzọ dabere na mkpokọta glucose, ebe ọ na-ebelata oke glucagon n'ụzọ dabere na mkpokọta glucose.
Ya mere, mgbe glucose ọbara na-ebili, a na-akpali mmepụta insulin, ebe a na-egbochi secretion glucagon.N'ụzọ dị iche, liraglutide na-ebelata mmepụta insulin n'oge hypoglycemia na-enweghị emetụta secretion glucagon.Usoro hypoglycemic nke liraglutide gụnyekwara ntakịrị ogologo oge ịwụfu afọ.Liraglutide na-ebelata ibu ahụ yana oke abụba site na ibelata agụụ na oriri ume.
